Yatharth Hospitals: Targets, beds, key levels in 2026

Stock in focus as price swings widen

Yatharth Hospital & Trauma Care Services (NSE: YATHARTH) has been in focus after a sharp move in a single session, with commentary noting the stock rose nearly 9% even as broader markets were under pressure. Market data points in the provided feed show the stock trading in the low-₹800 range, with different snapshots reporting prices such as ₹809.8 (as of 26 May, 2026) and ₹820.55 as a “current share price” reference in a separate table.

The interest is also being driven by brokerage notes that link the investment case to bed capacity expansion, improving occupancy, and changes in business mix. At the same time, analyst targets and valuation assumptions vary widely, reflecting different views on execution, margins, and specific uncertainties cited in at least one note.

Latest available market snapshot (26 May, 2026)

As of 26 May, 2026, the stock price is stated at ₹809.8. The same snapshot shows intraday movement between ₹806.00 and ₹844.80. On a 52-week basis, the feed lists a 52-week high of ₹889.90 and a 52-week low of ₹485.00.

Liquidity indicators provided include an Average Traded Price (ATP) of ₹827.59, and a Last Traded Quantity at Last Traded Price (LTQ@LTP) of 27 shares at ₹809.80. The stock is also stated to be within a circuit range of ₹656.45 to ₹984.65. A “Value” figure of ₹41.45 crore is also provided in the same section.

Bid-ask and key reference points

The data includes a bid/ask quote of ₹823.15 / ₹825.00 at one point in the feed, highlighting that real-time quotes can shift within a short span. Another top-line figure in the input shows ₹827.35 with a move of 11.00 (1.35%), but the context around that print is not fully shown.

Separately, a table titled “Historical stock prices” lists a “Current Share Price” of ₹820.55, a 52-week high of ₹887.85, and a 52-week low of ₹485.00. The 52-week low is consistent across the two references, while the 52-week high differs marginally from the ₹889.90 figure shown elsewhere.

What analysts are saying on target prices

Multiple target prices appear in the feed, and they are not consistent across sources. Several lines repeat that analysts kept their price target steady at ₹941.67, citing unchanged assumptions around discount rate, expected revenue growth, profit margin, and future P/E. Another line notes a nudge up in target from ₹931.25 to about ₹941.67, driven by updated assumptions around revenue growth, profit margins, and forward P/E, while keeping the discount rate unchanged.

In contrast, another statement says the consensus price target “has been raised to ₹633.33,” attributing the change to increased valuation expectations despite a lower net profit margin and a higher future P/E multiple. The feed also contains an “Analysts' Consensus” block showing a mean consensus of OUTPERFORM from 3 analysts, with a last close price of ₹716.15 and an average target price of ₹780 (high ₹850, low ₹740).

Nuvama’s coverage note: growth, beds, and valuation multiples

A domestic brokerage, Nuvama, projects a 30% revenue CAGR and 31% EBITDA CAGR over FY25-28E, supported by a planned scale-up of bed capacity from around 2,500 beds in FY26E to nearly 5,000 by FY30E. In the same note, the stock is described as trading at 17x FY27E EV/EBITDA at current market prices.

Nuvama also initiated coverage with a ‘Buy’ rating and a target price of ₹920, valuing the company at around 20x H1FY28E EV/EBITDA. The thesis references improvement levers such as higher occupancy, mix optimisation, and ARPOB expansion, but also flags near-term margin pressure linked to expansion in one market commentary segment.

Operating drivers mentioned: occupancy, ARPOB, and specialty mix

The feed mentions that Yatharth’s three mature Noida hospitals are expected to clock around 14% annual growth as occupancy improves to 75% and the specialty and payor mix is optimised. This, in turn, is linked to a projected 7% rise in ARPOB.

Another section highlights occupancy improvement potential, including “material improvement in occupancy” for Faridabad hospitals (from 31% currently) and Noida Extension/Greater Noida (from 60%/65%). The same note mentions an intent to reduce dependence on government business over time, stating the current dependence is around 40%.

Expansion steps and capex detail cited

The feed contains an Oct-24 update that Yatharth acquired two hospitals: a 400-bed unit in Faridabad and a 300+ bed unit in Delhi, with capex of around ₹250 crore. This is presented as aligned with a goal of achieving bed capacity of around 3,000 by FY28.

The same set of notes expects growth to be fuelled by expansions and by improving specialty mix, with focus areas stated as oncology, neuroscience, and nephrology.

A separate brokerage cut: multiple derating and uncertainties

Not all notes are uniformly positive on valuation. One brokerage states it marginally cut FY25 estimates by 6% while broadly maintaining FY26/27 estimates, but reduced the target multiple to 15x average FY26/27 EBITDA (from 20x earlier). The reason cited is uncertainties related to “IT liabilities” and expenses related to acquisitions.

That note retains a ‘BUY’ rating but revises the target price to ₹620 from ₹800. It also repeats an expectation of revenue/EBITDA/PAT CAGR of 38%/33%/33% over FY24-27E, supported by specialty mix and ARPOB improvements, higher occupancy, and bed expansion plans.

Key numbers at a glance

Analyst targets: wide dispersion across notes

Market impact: what changes investors are tracking

The immediate market impact in the feed is primarily about volatility and repricing around expansion expectations and valuation. The stock has seen sharp moves in a session and is trading in a band in the low-₹800s based on the market snapshot provided.

From a fundamentals lens, the key monitoring variables in the notes are bed additions, the pace of occupancy improvement (including the specific baseline numbers quoted for Faridabad and Noida Extension/Greater Noida), and whether ARPOB improves as projected. Brokerages also explicitly tie valuation to EV/EBITDA multiples, citing 17x FY27E EV/EBITDA at current prices in one note.

Analysis: why targets differ so sharply

The target dispersion reflects two competing narratives present in the feed. One is an expansion-led growth story with quantified capacity plans and occupancy improvement assumptions, supported by explicit valuation frameworks (such as initiating coverage at ~20x EV/EBITDA). The other is caution around uncertainties and potential costs tied to acquisitions and “IT liabilities,” which leads to multiple derating and a lower target price even while retaining a ‘BUY’ stance.

This mix of growth visibility and execution risk often produces sharply different outcomes in valuation models, especially when the same company can be valued using different forward windows (FY26, FY27, H1FY28) and different multiples. The feed also shows that some targets are presented as steady due to unchanged assumptions, while others are revised due to updates in assumptions or risk perceptions.

Conclusion

Yatharth Hospital & Trauma Care Services is being tracked closely as it executes on hospital acquisitions and bed capacity expansion, with broker notes highlighting occupancy, ARPOB, and mix optimisation as key operational drivers. Analyst targets in the provided material range from ₹620 to around ₹942, reflecting a split between expansion-led upside views and concerns that have led to valuation multiple cuts. The next set of updates investors will watch are those that confirm progress on capacity ramp-up, occupancy improvements, and any developments around the uncertainties cited in brokerage notes.